{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:26:37Z","timestamp":1788279997793,"version":"build-2803163510"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573699"],"award-info":[{"award-number":["82573699"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272626"],"award-info":[{"award-number":["82272626"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Program of Shanghai Science and Technology Committee","award":["20Z11900300"],"award-info":[{"award-number":["20Z11900300"]}]},{"name":"Shanghai Clinical Research Project of Shanghai Shenkang Hospital Development Center","award":["SHDC2020CR4068"],"award-info":[{"award-number":["SHDC2020CR4068"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Young2023-0023"],"award-info":[{"award-number":["Y-Young2023-0023"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00983-3","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:45:47Z","timestamp":1786369547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era"],"prefix":"10.1186","volume":"14","author":[{"given":"Xinyue","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Weng","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"20","key":"983_CR1","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1056\/NEJMcp2402691","volume":"392","author":"K Raghav","year":"2025","unstructured":"Raghav K. Cancer of Unknown Primary Site. N Engl J Med. 2025;392(20):2035\u201347.","journal-title":"N Engl J Med"},{"issue":"4","key":"983_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1634\/theoncologist.12-4-418","volume":"12","author":"P George","year":"2007","unstructured":"George P, Evangelos B, Nicholas P. Cancer of unknown primary site: missing primary or missing biology? Oncologist. 2007;12(4):418\u201325.","journal-title":"Oncologist"},{"issue":"9824","key":"983_CR3","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428\u201335.","journal-title":"Lancet"},{"issue":"3","key":"983_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jare.2014.11.007","volume":"6","author":"N Pavlidis","year":"2015","unstructured":"Pavlidis N, Khaled H, Gaafar R. A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists. J Adv Res. 2015;6(3):375\u201382.","journal-title":"J Adv Res"},{"issue":"8","key":"983_CR5","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41591-023-02482-6","volume":"29","author":"M Intae","year":"2023","unstructured":"Intae M, Jaclyn L, C BS. Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nat Med. 2023;29(8):2057\u201367.","journal-title":"Nat Med"},{"key":"983_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canep.2019.06.006","volume":"61","author":"E Rassy","year":"2019","unstructured":"Rassy E, Nicholas P. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 2019;61:139\u201341.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"983_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2967\/jnumed.123.266556","volume":"65","author":"B Gu","year":"2024","unstructured":"Gu B, Yang Z, Du X, Xu X, Ou X, Xia Z, et al. Imaging of Tumor Stroma Using (68)Ga-FAPI PET\/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial. J Nucl Med. 2024;65(3):365\u201371.","journal-title":"J Nucl Med"},{"issue":"1","key":"983_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1186\/s12885-023-11563-1","volume":"23","author":"R Min","year":"2023","unstructured":"Min R, Xu C, Liqing J, Qianming B, Xiaoli Z, Xichun H, et al. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China. BMC Cancer. 2023;23(1):1175.","journal-title":"BMC Cancer"},{"issue":"3","key":"983_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s41669-017-0051-2","volume":"2","author":"MB Hannouf","year":"2018","unstructured":"Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, et al. The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study. Pharmacoecon Open. 2018;2(3):255\u201370.","journal-title":"Pharmacoecon Open"},{"key":"983_CR10","doi-asserted-by":"crossref","unstructured":"L W, K H, D Z, K D, K R, K H, et al. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective. J Cancer Res Clin Oncol. 2023;149(11):8225\u201334.","DOI":"10.1007\/s00432-023-04741-y"},{"issue":"1","key":"983_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/clinchem\/hvad180","volume":"70","author":"P Maria","year":"2024","unstructured":"Maria P, Tilmann B, Cornelia C, Harriet W, Bianca K, Thomas H, et al. Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary. Clin Chem. 2024;70(1):297\u2013306.","journal-title":"Clin Chem"},{"issue":"Suppl 5","key":"983_CR12","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v133\u20138.","journal-title":"Ann Oncol"},{"key":"983_CR13","doi-asserted-by":"publisher","first-page":"102000","DOI":"10.1016\/j.canep.2021.102000","volume":"74","author":"B YooKyung","year":"2021","unstructured":"YooKyung B, Dayeon P, Jiwon L, HyunSook L, YoungJoo W. Descriptive epidemiology of cancer of unknown primary in South Korea, 1999\u20132017. Cancer Epidemiol. 2021;74:102000.","journal-title":"Cancer Epidemiol"},{"key":"983_CR14","doi-asserted-by":"crossref","unstructured":"Wong B, Liu J, Yeo S, Akurang D, Lo A, Xu YH, et al. Evolution in the diagnosis and treatment of carcinoma of unknown primary: a multicenter Canadian analysis. Oncologist. 2024;30(7).","DOI":"10.1093\/oncolo\/oyae298"},{"issue":"14","key":"983_CR15","first-page":"2026","volume":"43","author":"P George","year":"2007","unstructured":"George P, Vassilios G, Nicholas P. Switching benchmarks in cancer of unknown primary: From autopsy to microarray European. J Cancer. 2007;43(14):2026\u201336.","journal-title":"J Cancer"},{"issue":"14","key":"983_CR16","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/S0959-8049(03)00547-1","volume":"39","author":"N Pavlidis","year":"2003","unstructured":"Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39(14):1990\u20132005.","journal-title":"Eur J Cancer"},{"issue":"11","key":"983_CR17","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s12094-018-1899-z","volume":"20","author":"F Losa","year":"2018","unstructured":"Losa F, Iglesias L, Pane M, Sanz J, Nieto B, Fuste V, et al. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol. 2018;20(11):1361\u201372.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"983_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.17305\/bjbms.2016.1495","volume":"16","author":"S Uzunoglu","year":"2016","unstructured":"Uzunoglu S, Erdogan B, Kodaz H, Cinkaya A, Turkmen E, Hacibekiroglu I, et al. Unknown primary adenocarcinomas: a single-center experience. Bosn J Basic Med Sci. 2016;16(4):292\u20137.","journal-title":"Bosn J Basic Med Sci"},{"issue":"4","key":"983_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3904\/kjim.2002.17.4.234","volume":"17","author":"SS Young","year":"2002","unstructured":"Young SS, Seog KW, Ran LH, Sik JH, Yong OS, Hyang KJ, et al. Adenocarcinoma of unknown primary site. Korean J Intern Med. 2002;17(4):234\u20139.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"983_CR20","doi-asserted-by":"publisher","first-page":"e31181","DOI":"10.1371\/journal.pone.0031181","volume":"7","author":"K Hashimoto","year":"2012","unstructured":"Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, et al. Immunohistochemical profile for unknown primary adenocarcinoma. PLoS ONE. 2012;7(1):e31181.","journal-title":"PLoS ONE"},{"issue":"23","key":"983_CR21","doi-asserted-by":"publisher","first-page":"12440","DOI":"10.18632\/oncotarget.2574","volume":"5","author":"G Zoran","year":"2014","unstructured":"Zoran G, Z MS, Semir V, Ryan B, Andreas DBG. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget. 2014;5(23):12440\u20137.","journal-title":"Oncotarget"},{"issue":"1","key":"983_CR22","first-page":"27","volume":"75","author":"P George","year":"2009","unstructured":"George P, Nicholas P. Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Reviews Oncol Hematol. 2009;75(1):27\u201342.","journal-title":"Crit Reviews Oncol Hematol"},{"issue":"12","key":"983_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1634\/theoncologist.2009-0112","volume":"14","author":"HJ D","year":"2009","unstructured":"D HJ, B MP RSDSTD. Paclitaxel\/carboplatin plus bevacizumab\/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist. 2009;14(12):1189\u201397.","journal-title":"Oncologist"},{"issue":"4","key":"983_CR24","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ijrobp.2007.04.039","volume":"69","author":"D Beld\u00ec","year":"2007","unstructured":"Beld\u00ec D, Jereczek-Fossa BA, D\u2019Onofrio A, Gambaro G, Fiore MR, Pia F, et al. Role of Radiotherapy in the Treatment of Cervical Lymph Node Metastases From an Unknown Primary Site: Retrospective Analysis of 113 Patients. J Int J Radiation Oncol Biology Phys. 2007;69(4):1051\u20138.","journal-title":"J Int J Radiation Oncol Biology Phys"},{"issue":"2","key":"983_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ctrv.2003.10.001","volume":"30","author":"BA Jereczek-Fossa","year":"2003","unstructured":"Jereczek-Fossa BA, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. J Cancer Treat Reviews. 2003;30(2):153\u201364.","journal-title":"J Cancer Treat Reviews"},{"key":"983_CR26","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.2147\/CMAR.S204346","volume":"11","author":"K Dorobisz","year":"2019","unstructured":"Dorobisz K, Wlodarska-Polinska I, Pazdro-Zastawny K, Rutkowski T, Palka P, Dworzecki T, et al. The impact of the patient\u2019s condition, diagnostic procedures and treatment on the survival of carcinoma of unknown primary site patients. Cancer Manag Res. 2019;11:6603\u201314.","journal-title":"Cancer Manag Res"},{"issue":"8","key":"983_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/annonc\/mdg330","volume":"14","author":"A Argiris","year":"2003","unstructured":"Argiris A, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS, et al. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol. 2003;14(8):1306\u201311.","journal-title":"Ann Oncol"},{"issue":"6","key":"983_CR28","first-page":"2557","volume":"274","author":"AK Basel","year":"2017","unstructured":"Basel AK, Giorgos P, Maximilian L, Bernhard S, Christian R, Simeon BB, et al. Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 patients. J European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology -. Head Neck Surg. 2017;274(6):2557\u201366.","journal-title":"Head Neck Surg"},{"key":"983_CR29","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.2147\/CMAR.S319179","volume":"13","author":"M Pinkiewicz","year":"2021","unstructured":"Pinkiewicz M, Dorobisz K, Zatonski T. A Systematic Review of Cancer of Unknown Primary in the Head and Neck Region. Cancer Manag Res. 2021;13:7235\u201341.","journal-title":"Cancer Manag Res"},{"issue":"12","key":"983_CR30","first-page":"E281","volume":"87","author":"K Suren","year":"2017","unstructured":"Suren K, James C, Enyinnaya O. Transoral robotic surgery base of tongue mucosectomy for head and neck cancer of unknown primary. J ANZ J Surg. 2017;87(12):E281\u20134.","journal-title":"J ANZ J Surg"},{"key":"983_CR31","doi-asserted-by":"crossref","unstructured":"Ota I, Kitahara T. Cancer of unknown primary in the head and neck: diagnosis and treatment. J Auris Nasus Larynx. 2020;48(1).","DOI":"10.1016\/j.anl.2020.08.014"},{"issue":"10","key":"983_CR32","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1002\/hed.25858","volume":"41","author":"IGR Villejuif","year":"2019","unstructured":"Department of Medical Oncology, Villejuif IGR. Department of Medical Oncology HDdFUH, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon., Department of Otorhinolaryngology H, Neck Surgery UoB, Brescia, Italy., University of Ioannina I, Greece. Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. J Head neck. 2019;41(10):3700\u201311.","journal-title":"J Head neck"},{"issue":"8","key":"983_CR33","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41416-019-0723-z","volume":"122","author":"R Elie","year":"2020","unstructured":"Elie R, Tarek A, Nicholas P. Exploring the biological hallmarks of cancer of unknown primary: where do we stand today? Br J Cancer. 2020;122(8):1124\u201332.","journal-title":"Br J Cancer"},{"issue":"2","key":"983_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/annonc\/mdr306","volume":"23","author":"FA Greco","year":"2012","unstructured":"Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2012;23(2):298\u2013304.","journal-title":"Ann Oncol"},{"key":"983_CR35","doi-asserted-by":"crossref","unstructured":"SLMKSH. Cancer of unknown primary. BMJ. 2020;371:m4050.","DOI":"10.1136\/bmj.m4050"},{"key":"983_CR36","doi-asserted-by":"crossref","unstructured":"GL, GP, GF, NP. Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev. 2009;34(8):693\u2013700.","DOI":"10.1016\/j.ctrv.2008.05.005"},{"issue":"7","key":"983_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ctrv.2009.05.005","volume":"35","author":"V Golfinopoulos","year":"2009","unstructured":"Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009;35(7):570\u20133.","journal-title":"Cancer Treat Rev"},{"issue":"13","key":"983_CR38","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1200\/JCO.2006.09.3047","volume":"25","author":"DHJRSD Cindy","year":"2007","unstructured":"Cindy DHJRSD, S F, TD LSD, Anthony GF. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin oncology: official J Am Soc Clin Oncol. 2007;25(13):1747\u201352.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"983_CR39","doi-asserted-by":"crossref","unstructured":"Kazuo N, Shuichi H, Takashi I, Azusa K, Satoshi O, Kenji M, et al. A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Jpn J Clin Oncol. 2022;52(12).","DOI":"10.1093\/jjco\/hyac143"},{"issue":"Suppl 8","key":"983_CR40","first-page":"724","volume":"126","author":"JVC L CM","year":"2018","unstructured":"L CM JVC. cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy. Cancer Cytopathol. 2018;126(Suppl 8):724\u201337.","journal-title":"Cancer Cytopathol"},{"issue":"12","key":"983_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","volume":"8","author":"M Christophe","year":"2011","unstructured":"Christophe M, Yohann L, Karim F. Carcinomas of an unknown primary origin\u2013diagnosis and treatment. Nat Reviews Clin Oncol. 2011;8(12):701\u201310.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"7","key":"983_CR42","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","volume":"37","author":"HHKTTYAMT Koji","year":"2019","unstructured":"Koji HHKTTYAMT. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. J Clin oncology: official J Am Soc Clin Oncol. 2019;37(7):570\u20139.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"10452","key":"983_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","volume":"404","author":"A Kr\u00e4mer","year":"2024","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, Shiu KK, Cook N, Menezes JJ, et al. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet (London England). 2024;404(10452):527\u201339.","journal-title":"Lancet (London England)"},{"key":"983_CR44","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhao T, Xu M, Guo Y, Wang Q, Wang Y, et al. Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial. Nat Commun. 2026;17:6263.","DOI":"10.1038\/s41467-026-72745-6"},{"issue":"1","key":"983_CR45","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1038\/s41467-023-42400-5","volume":"14","author":"M Pouyiourou","year":"2023","unstructured":"Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Loffler H, et al. Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial. Nat Commun. 2023;14(1):6761.","journal-title":"Nat Commun"},{"key":"983_CR46","doi-asserted-by":"crossref","unstructured":"P RK, Bettzy S, D KD, A PS, S HD, Dipti J, et al. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022;10(5).","DOI":"10.1136\/jitc-2022-004822"},{"issue":"7","key":"983_CR47","first-page":"e27184","volume":"14","author":"RE Cox","year":"2022","unstructured":"Cox RE, Chakrabarti S. A Carcinoma of Unknown Primary (CUP) Patient Treated Successfully With Immunotherapy Upon Recognition of Deficient Mismatch Repair Signature on Liquid Biopsy: A Case Report. Cureus. 2022;14(7):e27184.","journal-title":"Cureus"},{"key":"983_CR48","doi-asserted-by":"publisher","first-page":"1181444","DOI":"10.3389\/fimmu.2023.1181444","volume":"14","author":"S Jin","year":"2023","unstructured":"Jin S, Hongming P, Weidong H. Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature. Front Immunol. 2023;14:1181444.","journal-title":"Front Immunol"},{"issue":"12","key":"983_CR49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/cac2.12111","volume":"40","author":"Z Hongqing","year":"2020","unstructured":"Hongqing Z. Abscopal effect of stereotactic radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy: Mechanisms, clinical efficacy, and issues. Cancer Commun (London England). 2020;40(12):649\u201354.","journal-title":"Cancer Commun (London England)"},{"issue":"8","key":"983_CR50","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S1470-2045(24)00344-9","volume":"25","author":"FA Greco","year":"2024","unstructured":"Greco FA, Labaki C, Rassy E. Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone. Lancet Oncol. 2024;25(8):955\u20136.","journal-title":"Lancet Oncol"},{"issue":"1","key":"983_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40291-024-00746-6","volume":"29","author":"P Qi","year":"2024","unstructured":"Qi P, Sun Y, Pang Y, Liu J, Cai X, Huang S, et al. Diagnostic Utility of a 90-Gene Expression Assay (Canhelp-Origin) for Patients with Metastatic Cancer with an Unclear or Unknown Diagnosis. Mol Diagn Ther. 2024;29(1):81\u20139.","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"983_CR52","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","volume":"25","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang X, Jiang S, Mo M, Wang Q, Wang Y, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. Lancet Oncol. 2024;25(8):1092\u2013102.","journal-title":"Lancet Oncol"},{"issue":"19","key":"983_CR53","doi-asserted-by":"publisher","first-page":"19394","DOI":"10.1002\/cam4.6532","volume":"12","author":"ME C","year":"2023","unstructured":"C ME, C BG, C DN. Assessing the utility of molecular diagnostic classification for cancers of unknown primary. Cancer Med. 2023;12(19):19394\u2013405.","journal-title":"Cancer Med"},{"key":"983_CR54","doi-asserted-by":"publisher","first-page":"101524","DOI":"10.1016\/j.lanepe.2025.101524","volume":"60","author":"C Dupain","year":"2026","unstructured":"Dupain C, Jacquin N, Latouche A, Neviere Z, Gestraud P, Hamza A, et al. Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis. Lancet Reg Health Eur. 2026;60:101524.","journal-title":"Lancet Reg Health Eur"},{"issue":"Suppl 10","key":"983_CR55","doi-asserted-by":"publisher","first-page":"x271","DOI":"10.1093\/annonc\/mds357","volume":"23","author":"KA Oien","year":"2012","unstructured":"Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol. 2012;23(Suppl 10):x271\u20137.","journal-title":"Ann Oncol"},{"issue":"4","key":"983_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/cancers10040108","volume":"10","author":"S Janick","year":"2018","unstructured":"Janick S, Elodie L-M, Marie-Christine M, Philippe R, Marius I. Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site. Cancers. 2018;10(4):108.","journal-title":"Cancers"},{"key":"983_CR57","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.yexmp.2022.104762","volume":"126","author":"D Dum","year":"2022","unstructured":"Dum D, Menz A, Volkel C, De Wispelaere N, Hinsch A, Gorbokon N, et al. Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Exp Mol Pathol. 2022;126:104762.","journal-title":"Exp Mol Pathol"},{"issue":"11","key":"983_CR58","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nrclinonc.2017.97","volume":"14","author":"MAM Sebasti\u00e1n","year":"2017","unstructured":"Sebasti\u00e1n MAM, Stergios B, et al. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Reviews Clin Oncol. 2017;14(11):682\u201394.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"983_CR59","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1038\/s41467-022-31666-w","volume":"13","author":"L Nguyen","year":"2022","unstructured":"Nguyen L, Van Hoeck A, Cuppen E. Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. Nat Commun. 2022;13(1):4013.","journal-title":"Nat Commun"},{"key":"983_CR60","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3389\/fonc.2019.01546","volume":"9","author":"S Kolling","year":"2019","unstructured":"Kolling S. Metastatic Cancer of Unknown Primary or Primary Metastatic Cancer? Front Oncol. 2019;9:1546.","journal-title":"Front Oncol"},{"key":"983_CR61","doi-asserted-by":"crossref","unstructured":"Krawczyk P, Jassem J, Wojas-Krawczyk K, Krzakowski M, Dziadziuszko R, Olszewski W. New genetic technologies in diagnosis and treatment of cancer of unknown primary. Cancers. 2022;14(14):3429.","DOI":"10.3390\/cancers14143429"},{"key":"983_CR62","doi-asserted-by":"crossref","unstructured":"Ma W, Wu H, Chen Y, Xu H, Jiang J, Du B, et al. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges. Brief Bioinform. 2024;25(2).","DOI":"10.1093\/bib\/bbae028"},{"issue":"10","key":"983_CR63","first-page":"820","volume":"8","author":"C-P Marta","year":"2022","unstructured":"Marta C-P, Alberto B-C, Manel E. Single cell cancer epigenetics Trends Cancer. 2022;8(10):820\u201338.","journal-title":"Single cell cancer epigenetics Trends Cancer"},{"issue":"5","key":"983_CR64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jmoldx.2011.04.004","volume":"13","author":"MG Erlander","year":"2011","unstructured":"Erlander MG, Ma X-J, Kesty NC, Bao L, Salunga R, Schnabel CA. Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification. J Mol Diagn. 2011;13(5):493\u2013503.","journal-title":"J Mol Diagn"},{"issue":"14","key":"983_CR65","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1158\/1078-0432.CCR-12-0920","volume":"18","author":"E KS","year":"2012","unstructured":"KS E, SC A, SP S, Yi, Z, Veena, Brittany C S, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin cancer research: official J Am Association Cancer Res. 2012;18(14):3952\u201360.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"key":"983_CR66","doi-asserted-by":"crossref","unstructured":"Tothill RW, Shi F, Paiman L, Bedo J, Kowalczyk A, Mileshkin L, et al. Development and validation of a gene expression tumour classifier for cancer of unknown primary. Pathology. 2015;47(1):7\u201312.","DOI":"10.1097\/PAT.0000000000000194"},{"key":"983_CR67","unstructured":"Dmitri T, Gauri V, Martin R, Timothy J, Christina M, Kenneth H, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. Cancer Res. 2009;69."},{"key":"983_CR68","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fonc.2019.00354","volume":"9","author":"Q Wang","year":"2019","unstructured":"Wang Q, Xu M, Sun Y, Chen J, Chen C, Qian C, et al. Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. Front Oncol. 2019;9:354.","journal-title":"Front Oncol"},{"issue":"2","key":"983_CR69","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/abbs\/gmz153","volume":"52","author":"N Qu","year":"2020","unstructured":"Qu N, Huang D, Xu Q, Wang J, Chen C, Ji Q, et al. Gene expression profiling of cells of origin of squamous cell carcinomas in head-and-neck, esophagus, and lung. Acta Biochim Biophys Sin (Shanghai). 2020;52(2):211\u20134.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"1","key":"983_CR70","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-022-03318-6","volume":"20","author":"W Sun","year":"2022","unstructured":"Sun W, Wu W, Wang Q, Yao Q, Feng Q, Wang Y, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. J Transl Med. 2022;20(1):114.","journal-title":"J Transl Med"},{"key":"983_CR71","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1746-1596-8-44","volume":"8","author":"A Lal","year":"2013","unstructured":"Lal A, Panos R, Marjanovic M, Walker M, Fuentes E, Kubicek GJ, et al. A gene expression profile test to resolve head & neck squamous versus lung squamous cancers. Diagn Pathol. 2013;8:44.","journal-title":"Diagn Pathol"},{"issue":"27","key":"983_CR72","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1200\/JCO.2007.14.6969","volume":"26","author":"MHHK vLR","year":"2008","unstructured":"vLR MHHK, Jan-Martijn K, H HH, Jelle W, vdHJJ M, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin oncology: official J Am Soc Clin Oncol. 2008;26(27):4435\u201341.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"1","key":"983_CR73","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12967-019-2082-1","volume":"17","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Ding Y, Wang Q, Sun Y, Teng X, Gao Q, et al. 90-gene signature assay for tissue origin diagnosis of brain metastases. J Transl Med. 2019;17(1):331.","journal-title":"J Transl Med"},{"key":"983_CR74","doi-asserted-by":"publisher","first-page":"725988","DOI":"10.3389\/fonc.2021.725988","volume":"11","author":"Q Wang","year":"2021","unstructured":"Wang Q, Li F, Jiang Q, Sun Y, Liao Q, An H, et al. Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study. Front Oncol. 2021;11:725988.","journal-title":"Front Oncol"},{"issue":"1","key":"983_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12935-021-01748-8","volume":"21","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Sun Y, Kuai Y, Fu G, An H, Chen J, et al. Gene expression profiling for the diagnosis of multiple primary malignant tumors. Cancer Cell Int. 2021;21(1):47.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"983_CR76","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1186\/s12885-024-13358-4","volume":"24","author":"J Liu","year":"2024","unstructured":"Liu J, Sun Y, Qi P, Wo Y, Pang Y, Xu Q, et al. Gene expression profiling for the diagnosis of male breast cancer. BMC Cancer. 2024;24(1):1584.","journal-title":"BMC Cancer"},{"issue":"10","key":"983_CR77","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran S, Martinez-Cardus A, Sayols S, Musulen E, Balana C, Estival-Gonzalez A, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(10):1386\u201395.","journal-title":"Lancet Oncol"},{"key":"983_CR78","doi-asserted-by":"publisher","first-page":"722808","DOI":"10.3389\/fonc.2021.722808","volume":"11","author":"Z Yi","year":"2021","unstructured":"Yi Z, Lei X, Dawei M, Jing W, Xinyu X, Youtao X. 90-Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary. Front Oncol. 2021;11:722808\u2013.","journal-title":"Front Oncol"},{"issue":"1","key":"983_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13148-024-01638-6","volume":"16","author":"M Sun","year":"2024","unstructured":"Sun M, Xu B, Chen C, Zhu Y, Li X, Chen K. Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel. Clin Epigenetics. 2024;16(1):25.","journal-title":"Clin Epigenetics"},{"key":"983_CR80","doi-asserted-by":"crossref","unstructured":"Liu X, Jiang H, Wang X. Advances in cancer research: current and future diagnostic and therapeutic strategies. Biosens (Basel). 2024;14(2).","DOI":"10.3390\/bios14020100"},{"issue":"10","key":"983_CR81","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/1878-0261.13026","volume":"15","author":"N Laprovitera","year":"2021","unstructured":"Laprovitera N, Riefolo M, Porcellini E, Durante G, Garajova I, Vasuri F, et al. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Mol Oncol. 2021;15(10):2732\u201351.","journal-title":"Mol Oncol"},{"issue":"6","key":"983_CR82","doi-asserted-by":"publisher","first-page":"100611","DOI":"10.1016\/j.esmoop.2022.100611","volume":"7","author":"LJ Schipper","year":"2022","unstructured":"Schipper LJ, Samsom KG, Snaebjornsson P, Battaglia T, Bosch LJW, Lalezari F, et al. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. ESMO Open. 2022;7(6):100611.","journal-title":"ESMO Open"},{"issue":"9","key":"983_CR83","doi-asserted-by":"publisher","first-page":"102332","DOI":"10.1016\/j.xcrm.2025.102332","volume":"6","author":"J Liu","year":"2025","unstructured":"Liu J, Yang M, Bi Y, Zhang J, Yang Y, Li Y, et al. Large language models enable tumor-type classification and localization of cancers of unknown primary from genomic data. Cell Rep Med. 2025;6(9):102332.","journal-title":"Cell Rep Med"},{"issue":"1","key":"983_CR84","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","volume":"15","author":"AM Conway","year":"2024","unstructured":"Conway AM, Pearce SP, Clipson A, Hill SM, Chemi F, Slane-Tan D, et al. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary. Nat Commun. 2024;15(1):3292.","journal-title":"Nat Commun"},{"key":"983_CR85","doi-asserted-by":"publisher","first-page":"101021","DOI":"10.1016\/j.neo.2024.101021","volume":"55","author":"J Hwang","year":"2024","unstructured":"Hwang J, Lee Y, Yoo SK, Kim JI. Image-based deep learning model using DNA methylation data predicts the origin of cancer of unknown primary. Neoplasia. 2024;55:101021\u2013.","journal-title":"Neoplasia"},{"issue":"14","key":"983_CR86","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1158\/1078-0432.CCR-12-0920","volume":"18","author":"SE Kerr","year":"2012","unstructured":"Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18(14):3952\u201360.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"983_CR87","first-page":"e70311","volume":"8","author":"Y Hao","year":"2025","unstructured":"Hao Y, Huang H, Huang D, Ruan J, Liu X, Zhang J. OncoTrace-TOO: Interpretable Machine Learning Framework for Cancer Tissue-of-Origin Identification Using Transcriptomic Signatures. Cancer Rep (Hoboken). 2025;8(8):e70311.","journal-title":"Cancer Rep (Hoboken)"},{"key":"983_CR88","doi-asserted-by":"crossref","unstructured":"Boys E, Liu J, Cai Z, Noor Z, Mackenzie KL, Aref A. Pan-cancer diagnostic proteomic signature of tissue-of-origin (TOO) using data-independent acquisition mass spectrometry (DIA-MS) from 1289 human tissue samples. J Clin Oncol 2023;41.","DOI":"10.1200\/JCO.2023.41.16_suppl.3120"},{"issue":"7","key":"983_CR89","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.ccell.2025.05.003","volume":"43","author":"JC Knol","year":"2025","unstructured":"Knol JC, Lyu M, Bottger F, Nunes Monteiro M, Pham TV, Rolfs F, et al. The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets. Cancer Cell. 2025;43(7):1328\u2013e468.","journal-title":"Cancer Cell"},{"issue":"1","key":"983_CR90","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1038\/s41467-022-31866-4","volume":"13","author":"L Mohrmann","year":"2022","unstructured":"Mohrmann L, Werner M, Oles M, Mock A, Uhrig S, Jahn A, et al. Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nat Commun. 2022;13(1):4485.","journal-title":"Nat Commun"},{"issue":"1","key":"983_CR91","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1038\/s41467-025-59661-x","volume":"16","author":"RJ Rebello","year":"2025","unstructured":"Rebello RJ, Posner A, Dong R, Prall OWJ, Sivakumaran T, Mitchell CB, et al. Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary. Nat Commun. 2025;16(1):4422.","journal-title":"Nat Commun"},{"issue":"3","key":"983_CR92","doi-asserted-by":"publisher","first-page":"101016","DOI":"10.1016\/j.tranon.2021.101016","volume":"14","author":"J Abraham","year":"2021","unstructured":"Abraham J, Heimberger AB, Marshall J, Heath E, Drabick J, Helmstetter A, et al. Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type. Transl Oncol. 2021;14(3):101016.","journal-title":"Transl Oncol"},{"issue":"1","key":"983_CR93","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12967-022-03362-2","volume":"20","author":"K Chen","year":"2022","unstructured":"Chen K, Zhang F, Yu X, Huang Z, Gong L, Xu Y, et al. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary. J Transl Med. 2022;20(1):158.","journal-title":"J Transl Med"},{"issue":"6","key":"983_CR94","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free. DNA Annals Oncol. 2020;31(6):745\u201359.","journal-title":"DNA Annals Oncol"},{"issue":"1","key":"983_CR95","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/13696998.2024.2413289","volume":"27","author":"D Isla","year":"2024","unstructured":"Isla D, \u00c1lvarez R, Arnal M, Arriola E, Azkarate A, Azkona E, et al. Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis. J Med Econ. 2024;27(1):11\u20138.","journal-title":"J Med Econ"},{"issue":"1","key":"983_CR96","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13148-025-01902-3","volume":"17","author":"M Ren","year":"2025","unstructured":"Ren M, Xu M, Chen C, Wei R, Yao Q, Jia L, et al. Mutational landscape and DNA methylation-based classification of squamous cell carcinoma and urothelial carcinoma. Clin Epigenetics. 2025;17(1):95.","journal-title":"Clin Epigenetics"},{"issue":"9","key":"983_CR97","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s12276-020-0422-0","volume":"52","author":"F Jean","year":"2020","unstructured":"Jean F, Kamil S, Fan Z. Single-cell transcriptomics in cancer: computational challenges and opportunities. Exp Mol Med. 2020;52(9):1452\u201365.","journal-title":"Exp Mol Med"},{"issue":"10","key":"983_CR98","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jmoldx.2021.07.009","volume":"23","author":"V Julien","year":"2021","unstructured":"Julien V, Ga\u00eblle P, Camille B, Nad\u00e8ge G, Delphine G, Anne V, et al. Identification of tissue of origin and guided therapeutic applications in cancers of unknown primary using deep learning and RNA sequencing (TransCUPtomics). J Mol diagnostics: JMD. 2021;23(10):1380\u201392.","journal-title":"J Mol diagnostics: JMD"},{"issue":"1","key":"983_CR99","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamaoncol.2019.3985","volume":"6","author":"A Penson","year":"2020","unstructured":"Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, et al. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncol. 2020;6(1):84\u201391.","journal-title":"JAMA Oncol"},{"issue":"1","key":"983_CR100","doi-asserted-by":"publisher","first-page":"e0280928","DOI":"10.1371\/journal.pone.0280928","volume":"18","author":"BT L","year":"2023","unstructured":"L BT, Emi S, Mayzie M, Joshua S, W BR, Daniel P, et al. Neoplastic signatures: Comparative proteomics of canine hepatobiliary neuroendocrine tumors to normal niche tissue. PLoS ONE. 2023;18(1):e0280928\u2013e.","journal-title":"PLoS ONE"},{"issue":"1","key":"983_CR101","doi-asserted-by":"publisher","first-page":"100476","DOI":"10.1016\/j.mcpro.2022.100476","volume":"22","author":"B Meltem","year":"2023","unstructured":"Meltem B, Petra E-G, Qiang LMJ, SR ZW, Zhanfang G, et al. Proteins in Tumor-Derived Plasma Extracellular Vesicles Indicate Tumor Origin Molecular &. Cell Proteom. 2023;22(1):100476.","journal-title":"Cell Proteom"},{"issue":"1","key":"983_CR102","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1038\/s41467-022-31666-w","volume":"13","author":"N Luan","year":"2022","unstructured":"Luan N, Arne VH, Edwin C. Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. Nat Commun. 2022;13(1):4013.","journal-title":"Nat Commun"},{"key":"983_CR103","doi-asserted-by":"crossref","unstructured":"Bohnenberger H, Kaderali L, Str\u00f6bel P, Yepes D, Plessmann U, Dharia NV, et al. Comparative proteomics reveals a diagnostic signature for pulmonary head-and-neck cancer metastasis. EMBO Mol Med. 2018;10(9).","DOI":"10.15252\/emmm.201708428"},{"issue":"1","key":"983_CR104","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1038\/s41467-022-31719-0","volume":"13","author":"Q Song","year":"2022","unstructured":"Song Q, Yang Y, Jiang D, Qin Z, Xu C, Wang H, et al. Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues. Nat Commun. 2022;13(1):4167.","journal-title":"Nat Commun"},{"issue":"1","key":"983_CR105","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-025-00885-w","volume":"14","author":"T Gong","year":"2026","unstructured":"Gong T, Lao IW, Chio CF, Zhang X, Ren M, Li W, et al. Machine learning-driven proteomics classifier deciphers tumor origins of primary and metastatic squamous cell carcinomas. Biomark Res. 2026;14(1):15.","journal-title":"Biomark Res"},{"issue":"5","key":"983_CR106","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297\u2013312.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"983_CR107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12943-022-01505-z","volume":"21","author":"W Li","year":"2022","unstructured":"Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21(1):25.","journal-title":"Mol Cancer"},{"issue":"4","key":"983_CR108","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.molonc.2014.12.003","volume":"9","author":"R Lebofsky","year":"2015","unstructured":"Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, Leroy Q, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol. 2015;9(4):783\u201390.","journal-title":"Mol Oncol"},{"issue":"5","key":"983_CR109","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","volume":"28","author":"MG Best","year":"2015","unstructured":"Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 2015;28(5):666\u201376.","journal-title":"Cancer Cell"},{"key":"983_CR110","doi-asserted-by":"crossref","unstructured":"Ravegnini G, Ferioli M, Morganti AG, Strigari L, Pantaleo MA, Nannini M, et al. Radiomics and artificial intelligence in uterine sarcomas: a systematic review. J Pers Med. 2021;11(11).","DOI":"10.3390\/jpm11111179"},{"issue":"18","key":"983_CR111","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.21037\/atm-20-4589","volume":"8","author":"B Chen","year":"2020","unstructured":"Chen B, Yang L, Zhang R, Luo W, Li W. Radiomics: an overview in lung cancer management-a narrative review. Ann Transl Med. 2020;8(18):1191.","journal-title":"Ann Transl Med"},{"key":"983_CR112","doi-asserted-by":"crossref","unstructured":"Capobianco E, Dominietto M. From medical imaging to radiomics: role of data science for advancing precision health. J Pers Med. 2020;10(1).","DOI":"10.3390\/jpm10010015"},{"issue":"1","key":"983_CR113","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41597-024-03634-0","volume":"11","author":"Z Gong","year":"2024","unstructured":"Gong Z, Xu T, Peng N, Cheng X, Niu C, Wiestler B, et al. A Multi-Center, Multi-Parametric MRI Dataset of Primary and Secondary Brain Tumors. Sci Data. 2024;11(1):789.","journal-title":"Sci Data"},{"key":"983_CR114","doi-asserted-by":"crossref","unstructured":"LM Y, CT Y, WDF K, Melissa Z, Maha S, Jana L, et al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594(7861):106\u201310.","DOI":"10.1038\/s41586-021-03512-4"},{"issue":"5","key":"983_CR115","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/s41591-024-02915-w","volume":"30","author":"F Tian","year":"2024","unstructured":"Tian F, Liu D, Wei N, Fu Q, Sun L, Liu W, et al. Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning. Nat Med. 2024;30(5):1309\u201319.","journal-title":"Nat Med"},{"key":"983_CR116","doi-asserted-by":"crossref","unstructured":"Lu S, Pang Y, Wen H, Hu L, Zhou X, Yang X, et al. Deepath-SCC: a deep learning model for accurate tissue origin identification in squamous cell carcinoma. NPJ Precis Oncol. 2026;10(1).","DOI":"10.1038\/s41698-026-01405-1"},{"issue":"5","key":"983_CR117","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/path.5028","volume":"244","author":"LA Cooper","year":"2018","unstructured":"Cooper LA, Demicco EG, Saltz JH, Powell RT, Rao A, Lazar AJ. PanCancer insights from The Cancer Genome Atlas: the pathologist\u2019s perspective. J Pathol. 2018;244(5):512\u201324.","journal-title":"J Pathol"},{"key":"983_CR118","doi-asserted-by":"crossref","unstructured":"He BDC, Lang J, et al. A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation BBA -. Mol Basis Disease. 2020;1866(11):165916.","DOI":"10.1016\/j.bbadis.2020.165916"},{"issue":"23","key":"983_CR119","first-page":"4129","volume":"34","author":"S Kun","year":"2018","unstructured":"Kun S, Jiguang W, Huating W, Hao S. GeneCT: a generalizable cancerous status and tissue origin classifier for pan-cancer biopsies. Bioinf (Oxford England). 2018;34(23):4129\u201330.","journal-title":"Bioinf (Oxford England)"},{"issue":"1","key":"983_CR120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13148-024-01657-3","volume":"16","author":"S Leonhard","year":"2024","unstructured":"Leonhard S, Atsuko K, Fabian S, Benedikt S, Jakob R, Katharina H, et al. Head and neck cancer of unknown primary: unveiling primary tumor sites through machine learning on DNA methylation profiles. Clin Epigenetics. 2024;16(1):47.","journal-title":"Clin Epigenetics"},{"key":"983_CR121","doi-asserted-by":"publisher","first-page":"619330","DOI":"10.3389\/fcell.2021.619330","volume":"9","author":"L Haiyan","year":"2021","unstructured":"Haiyan L, Chun Q, Bo W, Pingping B, Geng T, Xueliang Z, et al. Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin. Front cell Dev biology. 2021;9:619330.","journal-title":"Front cell Dev biology"},{"key":"983_CR122","doi-asserted-by":"publisher","first-page":"632761","DOI":"10.3389\/fgene.2021.632761","volume":"12","author":"C Sijie","year":"2021","unstructured":"Sijie C, Wenjing Z, Jinghui T, Jian L, Bo W, Xiaofei M, et al. A Novel XGBoost Method to Infer the Primary Lesion of 20 Solid Tumor Types From Gene Expression Data. Front Genet. 2021;12:632761.","journal-title":"Front Genet"},{"issue":"1","key":"983_CR123","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1038\/s41467-023-41015-0","volume":"14","author":"Z Shirong","year":"2023","unstructured":"Shirong Z, Shutao H, Xin Z, Yunfei W, Qionghuan X, Xianrang S, et al. DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues. Nat Commun. 2023;14(1):5686.","journal-title":"Nat Commun"},{"issue":"4","key":"983_CR124","first-page":"378","volume":"256","author":"L Maximilian","year":"2021","unstructured":"Maximilian L, David C, Philipp S, Annika L, Ulrich S, KlausRobert M, et al. Machine Learning Models Predict the Primary Sites of Head and Neck Squamous Cell Carcinoma Metastases Based on DNA Methylation. J Pathol. 2021;256(4):378\u201387.","journal-title":"J Pathol"},{"issue":"10","key":"983_CR125","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jmoldx.2021.07.009","volume":"23","author":"V Julien","year":"2021","unstructured":"Julien V, Ga\u00eblle P, Camille B, Nad\u00e8ge G, Delphine G, Anne V, et al. Identification of tissue of origin and guided therapeutic applications in cancers of unknown primary using deep learning and RNA sequencing (TransCUPtomics). J Mol Diagn. 2021;23(10):1380\u201392.","journal-title":"J Mol Diagn"},{"key":"983_CR126","doi-asserted-by":"crossref","unstructured":"Jeong Y, Chu J, Kang J, Baek S, Lee JH, Jung DS, et al. Application of transcriptome-based gene set featurization for machine learning model to predict the origin of metastatic cancer. Curr Issues Mol Biol. 2024;46(7):7291\u2013302.","DOI":"10.3390\/cimb46070432"},{"issue":"1","key":"983_CR127","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13073-021-00968-x","volume":"13","author":"ATK Olga","year":"2021","unstructured":"Olga ATK, Andrew K, D. WE B, Nicola VPJ. Deep learning in cancer diagnosis, prognosis and treatment selection. Genome Med. 2021;13(1):152.","journal-title":"Genome Med"},{"issue":"1","key":"983_CR128","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41467-019-13825-8","volume":"11","author":"J Wei","year":"2020","unstructured":"Wei J, Gurnit A, Paz P, Rosa K, Edwin C, Alexandra D, et al. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2020;11(1):728.","journal-title":"Nat Commun"},{"key":"983_CR129","doi-asserted-by":"crossref","unstructured":"Enrico M, Alexander F, D MH, Austin H, Samuel M, Stuart L, et al. Developmental deconvolution for classification of cancer origin. Cancer Discov. 2022;12(11).","DOI":"10.1158\/2159-8290.CD-21-1443"},{"issue":"1","key":"983_CR130","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","volume":"15","author":"CA Marie","year":"2024","unstructured":"Marie CA, Alexandra PPS, HS CM, Francesca C, Dan ST, et al. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary. Nat Commun. 2024;15(1):3292.","journal-title":"Nat Commun"},{"issue":"9","key":"983_CR131","doi-asserted-by":"publisher","first-page":"101173","DOI":"10.1016\/j.xcrm.2023.101173","volume":"4","author":"MWJ Runyu","year":"2023","unstructured":"Runyu MWJ, G H, Jimin DE, Rossana T. Deep learning integrates histopathology and proteogenomics at a pan-cancer level. Cell Rep Med. 2023;4(9):101173.","journal-title":"Cell Rep Med"},{"issue":"1","key":"983_CR132","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s43441-019-00030-4","volume":"54","author":"D Calaprice-Whitty","year":"2019","unstructured":"Calaprice-Whitty D, Galil K, Salloum W, Zariv A, Jimenez B. Improving Clinical Trial Participant Prescreening With Artificial Intelligence (AI): A Comparison of the Results of AI-Assisted vs Standard Methods in 3 Oncology Trials. Therapeutic Innov Regul Sci. 2019;54(1):69\u201374.","journal-title":"Therapeutic Innov Regul Sci"},{"issue":"1","key":"983_CR133","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1038\/s41467-024-49153-9","volume":"15","author":"A Juan Ramon","year":"2024","unstructured":"Juan Ramon A, Parmar C, Carrasco-Zevallos OM, Csiszer C, Yip SSF, Raciti P, et al. Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial. Nat Commun. 2024;15(1):4690.","journal-title":"Nat Commun"},{"key":"983_CR134","doi-asserted-by":"crossref","unstructured":"Coppola F, Giannini V, Gabelloni M, Panic J, Defeudis A, Lo Monaco S, et al. Radiomics and magnetic resonance imaging of rectal cancer: from engineering to clinical practice. Diagnostics (Basel). 2021;11(5).","DOI":"10.3390\/diagnostics11050756"},{"issue":"4","key":"983_CR135","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s13244-018-0639-9","volume":"9","author":"R Yamashita","year":"2018","unstructured":"Yamashita R, Nishio M, Do RKG, Togashi K. Convolutional neural networks: an overview and application in radiology. Insights Imaging. 2018;9(4):611\u201329.","journal-title":"Insights Imaging"},{"issue":"4","key":"983_CR136","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441\u20136.","journal-title":"Eur J Cancer"},{"issue":"11","key":"983_CR137","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","volume":"16","author":"K Bera","year":"2019","unstructured":"Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16(11):703\u201315.","journal-title":"Nat Rev Clin Oncol"},{"key":"983_CR138","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3389\/fphar.2020.01177","volume":"11","author":"SK Patel","year":"2020","unstructured":"Patel SK, George B, Rai V. Artificial Intelligence to Decode Cancer Mechanism: Beyond Patient Stratification for Precision Oncology. Front Pharmacol. 2020;11:1177.","journal-title":"Front Pharmacol"},{"issue":"6","key":"983_CR139","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s13244-018-0657-7","volume":"9","author":"E Neri","year":"2018","unstructured":"Neri E, Del Re M, Paiar F, Erba P, Cocuzza P, Regge D, et al. Radiomics and liquid biopsy in oncology: the holons of systems medicine. Insights Imaging. 2018;9(6):915\u201324.","journal-title":"Insights Imaging"},{"issue":"5","key":"983_CR140","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.tibtech.2019.12.021","volume":"38","author":"D Ho","year":"2020","unstructured":"Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, et al. Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol. 2020;38(5):497\u2013518.","journal-title":"Trends Biotechnol"},{"issue":"5","key":"983_CR141","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4048\/jbc.2023.26.e45","volume":"26","author":"JS Ahn","year":"2023","unstructured":"Ahn JS, Shin S, Yang SA, Park EK, Kim KH, Cho SI, et al. Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine. J Breast Cancer. 2023;26(5):405\u201335.","journal-title":"J Breast Cancer"},{"key":"983_CR142","doi-asserted-by":"publisher","first-page":"217348","DOI":"10.1016\/j.canlet.2024.217348","volume":"611","author":"K Orostica","year":"2024","unstructured":"Orostica K, Mardones F, Bernal YA, Molina S, Orchard M, Verdugo RA, et al. Advances in machine learning for tumour classification in cancer of unknown primary: A mini-review. Cancer Lett. 2024;611:217348.","journal-title":"Cancer Lett"},{"key":"983_CR143","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.critrevonc.2025.104963","volume":"216","author":"Y Hu","year":"2025","unstructured":"Hu Y, Liang S, Zhou X, Zeng Z, Ding J, Hua D. Artificial intelligence enabled tumor diagnosis and treatment: Status, breakthroughs and challenges. Crit Rev Oncol Hematol. 2025;216:104963.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"983_CR144","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1038\/s41598-025-86536-4","volume":"15","author":"Z Bashir","year":"2025","unstructured":"Bashir Z, Lin M, Feragen A, Mikolaj K, Taksoe-Vester C, Christensen AN, et al. Clinical validation of explainable AI for fetal growth scans through multi-level, cross-institutional prospective end-user evaluation. Sci Rep. 2025;15(1):2074.","journal-title":"Sci Rep"},{"issue":"11","key":"983_CR145","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1109\/TNNLS.2020.3027314","volume":"32","author":"E Tjoa","year":"2021","unstructured":"Tjoa E, Guan C. A Survey on Explainable Artificial Intelligence (XAI): Toward Medical XAI. IEEE Trans Neural Netw Learn Syst. 2021;32(11):4793\u2013813.","journal-title":"IEEE Trans Neural Netw Learn Syst"},{"key":"983_CR146","doi-asserted-by":"publisher","first-page":"102470","DOI":"10.1016\/j.media.2022.102470","volume":"79","author":"BHM van der Velden","year":"2022","unstructured":"van der Velden BHM, Kuijf HJ, Gilhuijs KGA, Viergever MA. Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med Image Anal. 2022;79:102470.","journal-title":"Med Image Anal"},{"key":"983_CR147","doi-asserted-by":"crossref","unstructured":"Gregory H, Grossman MKH. Readiness for artificial intelligence in biobanking. Biopreserv Biobank. 2023;21(2).","DOI":"10.1089\/bio.2023.29121.editorial"},{"issue":"9","key":"983_CR148","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/17434440.2025.2531295","volume":"22","author":"E Niemiec","year":"2025","unstructured":"Niemiec E, Minssen T, Boland PA, McEntee PD, Cahill RA. Legal and regulatory challenges in multi-country data-driven projects developing and validating medical AI systems in the EU. Expert Rev Med Devices. 2025;22(9):925\u201337.","journal-title":"Expert Rev Med Devices"},{"issue":"1","key":"983_CR149","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41746-024-01232-3","volume":"7","author":"M Aboy","year":"2024","unstructured":"Aboy M, Minssen T, Vayena E. Navigating the EU AI Act: implications for regulated digital medical products. NPJ Digit Med. 2024;7(1):237.","journal-title":"NPJ Digit Med"},{"key":"983_CR150","doi-asserted-by":"publisher","first-page":"1403047","DOI":"10.3389\/fdgth.2025.1403047","volume":"7","author":"SP Oei","year":"2025","unstructured":"Oei SP, Bakkes T, Mischi M, Bouwman RA, van Sloun RJG, Turco S. Artificial intelligence in clinical decision support and the prediction of adverse events. Front Digit Health. 2025;7:1403047.","journal-title":"Front Digit Health"},{"key":"983_CR151","doi-asserted-by":"crossref","unstructured":"Bani MA. Smart lies and sharp eyes: pragmatic artificial intelligence for cancer pathology: promise, pitfalls, and access pathways. Cancers (Basel). 2026;18(3).","DOI":"10.3390\/cancers18030421"},{"issue":"3","key":"983_CR152","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/19475535261445907","volume":"24","author":"NK Tran","year":"2026","unstructured":"Tran NK, Dhir R, Rashidi H. Biobanking in the Era of Artificial Intelligence: Convergence, Challenges, and Opportunities. Biopreserv Biobank. 2026;24(3):195\u2013205.","journal-title":"Biopreserv Biobank"},{"key":"983_CR153","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fbioe.2020.00394","volume":"8","author":"B He","year":"2020","unstructured":"He B, Lang J, Wang B, Liu X, Lu Q, He J, et al. TOOme: A Novel Computational Framework to Infer Cancer Tissue-of-Origin by Integrating Both Gene Mutation and Expression. Front Bioeng Biotechnol. 2020;8:394.","journal-title":"Front Bioeng Biotechnol"},{"key":"983_CR154","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fgene.2020.00674","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu X, Li L, Peng L, Wang B, Lang J, Lu Q, et al. Predicting Cancer Tissue-of-Origin by a Machine Learning Method Using DNA Somatic Mutation Data. Front Genet. 2020;11:674.","journal-title":"Front Genet"},{"issue":"1","key":"983_CR155","doi-asserted-by":"publisher","first-page":"9669","DOI":"10.1038\/s41598-022-13665-5","volume":"12","author":"J Hong","year":"2022","unstructured":"Hong J, Hachem LD, Fehlings MG. A deep learning model to classify neoplastic state and tissue origin from transcriptomic data. Sci Rep. 2022;12(1):9669.","journal-title":"Sci Rep"},{"issue":"4","key":"983_CR156","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40291-023-00650-5","volume":"27","author":"J Michuda","year":"2023","unstructured":"Michuda J, Breschi A, Kapilivsky J, Manghnani K, McCarter C, Hockenberry AJ, et al. Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin. Mol Diagn Ther. 2023;27(4):499\u2013511.","journal-title":"Mol Diagn Ther"},{"key":"983_CR157","doi-asserted-by":"publisher","first-page":"632761","DOI":"10.3389\/fgene.2021.632761","volume":"12","author":"S Chen","year":"2021","unstructured":"Chen S, Zhou W, Tu J, Li J, Wang B, Mo X, et al. A Novel XGBoost Method to Infer the Primary Lesion of 20 Solid Tumor Types From Gene Expression Data. Front Genet. 2021;12:632761.","journal-title":"Front Genet"},{"issue":"2","key":"983_CR158","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41568-021-00408-3","volume":"22","author":"MBK Pegah","year":"2021","unstructured":"Pegah MBK, Rami K, Jianjiong V. Harnessing multimodal data integration to advance precision oncology. Nat Rev Cancer. 2021;22(2):114\u201326.","journal-title":"Nat Rev Cancer"},{"key":"983_CR159","doi-asserted-by":"publisher","first-page":"798748","DOI":"10.3389\/fgene.2021.798748","volume":"12","author":"L Pengfei","year":"2022","unstructured":"Pengfei L, Pan-Cancer DNA. Methylation Analysis and Tumor Origin Identification of Carcinoma of Unknown Primary Site Based on Multi-Omics. Front Genet. 2022;12:798748.","journal-title":"Front Genet"},{"issue":"5","key":"983_CR160","first-page":"336","volume":"63","author":"C Pauli","year":"2023","unstructured":"Pauli C. CUP syndrome-diagnostics from the perspective of pathology. Radiol (Heidelb). 2023;63(5):336\u201345.","journal-title":"Radiol (Heidelb)"},{"key":"983_CR161","doi-asserted-by":"publisher","first-page":"1181444","DOI":"10.3389\/fimmu.2023.1181444","volume":"14","author":"J Sheng","year":"2023","unstructured":"Sheng J, Pan H, Han W. Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature. Front Immunol. 2023;14:1181444.","journal-title":"Front Immunol"},{"issue":"1","key":"983_CR162","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1038\/s41598-021-85285-4","volume":"11","author":"HM Tah","year":"2021","unstructured":"Tah HM, RM A, Claudio A, James S, Saladin S, Mosharraf S. Integrated multi-omics analysis of ovarian cancer using variational autoencoders. Sci Rep. 2021;11(1):6265.","journal-title":"Sci Rep"},{"key":"983_CR163","doi-asserted-by":"publisher","first-page":"115589","DOI":"10.1016\/j.bcp.2023.115589","volume":"213","author":"K Sanjay","year":"2023","unstructured":"Sanjay K, Manita R, Kalpana T, Gaurav MI. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance. Biochem Pharmacol. 2023;213:115589.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"983_CR164","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ijms21010018","volume":"21","author":"G Scala","year":"2019","unstructured":"Scala G, Federico A, Fortino V, Greco D, Majello B. Knowledge Generation with Rule Induction in Cancer Omics. Int J Mol Sci. 2019;21(1):18.","journal-title":"Int J Mol Sci"},{"key":"983_CR165","doi-asserted-by":"publisher","first-page":"217350","DOI":"10.1016\/j.canlet.2024.217350","volume":"610","author":"B Yu","year":"2024","unstructured":"Yu B, Shao S, Ma W. Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy. Cancer Lett. 2024;610:217350.","journal-title":"Cancer Lett"},{"key":"983_CR166","doi-asserted-by":"publisher","first-page":"1199087","DOI":"10.3389\/fgene.2023.1199087","volume":"14","author":"WJ Sanyanda","year":"2023","unstructured":"Sanyanda WJ, Michael K. A review of multi-omics data integration through deep learning approaches for disease diagnosis, prognosis, and treatment. Front Genet. 2023;14:1199087\u2013.","journal-title":"Front Genet"},{"issue":"8","key":"983_CR167","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"ZZZ Yuanyuan","year":"2020","unstructured":"Yuanyuan ZZZ. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"983_CR168","first-page":"9795269","volume":"2016","author":"H Stefan","year":"2016","unstructured":"Stefan H, Lance P, David M, Farshid D. Clinically Meaningful Use of Blood Tumor Markers in Oncology. Biomed Res Int. 2016;2016:9795269.","journal-title":"Biomed Res Int"},{"key":"983_CR169","doi-asserted-by":"crossref","unstructured":"Noemi L, Mattia R, Elisa A, Christiane K, Martin P, Manuela F. Cancer of unknown primary: challenges and progress in clinical management. Cancers. 2021;13(3):451-.","DOI":"10.3390\/cancers13030451"},{"issue":"28","key":"983_CR170","doi-asserted-by":"publisher","first-page":"44322","DOI":"10.18632\/oncotarget.10035","volume":"7","author":"L Harald","year":"2016","unstructured":"Harald L, Nicole P, Mark K, Volker E, Thomas H, Philipp L, et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget. 2016;7(28):44322\u20139.","journal-title":"Oncotarget"},{"issue":"1","key":"983_CR171","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","volume":"1","author":"JS Ross","year":"2015","unstructured":"Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015;1(1):40\u20139.","journal-title":"JAMA Oncol"},{"key":"983_CR172","doi-asserted-by":"crossref","unstructured":"Hidetoshi H, Yuichi T, Hironobu M, Kohei A, Yoshihiko S, Hiroki U, et al. Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial. JAMA Oncol. 2020;6(12).","DOI":"10.1001\/jamaoncol.2020.4643"},{"key":"983_CR173","doi-asserted-by":"publisher","first-page":"113540","DOI":"10.1016\/j.ejca.2024.113540","volume":"200","author":"G Zaun","year":"2024","unstructured":"Zaun G, Borchert S, Metzenmacher M, Lueong S, Wiesweg M, Zaun Y, et al. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies. Eur J cancer (Oxford England: 1990). 2024;200:113540\u2013.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"4","key":"983_CR174","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/PPO.0000000000000383","volume":"25","author":"JAM Arjun Mittra","year":"2019","unstructured":"Arjun Mittra JAM. Future Approaches to Precision Oncology-Based Clinical Trials. Cancer J (Sudbury Mass). 2019;25(4):300\u20134.","journal-title":"Cancer J (Sudbury Mass)"},{"issue":"prepublish","key":"983_CR175","first-page":"102204","volume":"97","author":"O Timoth\u00e9e","year":"2021","unstructured":"Timoth\u00e9e O, Eugenio F, Intidhar LG, Yves DP, Veronica RB, Giulia B, et al. Redefining Cancer Of Unknown Primary: Is Precision Medicine Really Shifting The Paradigm? Cancer Treat Rev. 2021;97(prepublish):102204.","journal-title":"Cancer Treat Rev"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00983-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00983-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:04:51Z","timestamp":1788278691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00983-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":175,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00983-3","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a literature review and did not involve human participants, animal subjects, or any data requiring ethical approval.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YF S is an employee of Canhelp Genomics Co., Ltd. and has participated in the development and clinical validation of the 90 gene expression assay (Canhelp-Origin) discussed in this review. No other authors have competing interests to declare. All data and interpretations presented in this manuscript are derived from previously published peer reviewed literature. The review includes balanced discussion of alternative platforms with their respective advantages and limitations, and no specific product or commercial interest has been promoted over others.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}